A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Martin R. Farlow,Ravi Anand,John Messina,Richard Hartman,Jeffrey Veach

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

2000

Martin R. Farlow
Ravi Anand
John Messina
Richard Hartman
Jeffrey Veach

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer’s disease was evaluated in a 26-w

Keywords:

Anesthesia
Diabetes mellitus
Rivastigmine
Gastroenterology
Medicine
Degenerative disease
Alzheimer's disease
Rivastigmine Tartrate
Chemotherapy
Cholinesterase
Surgery
Central nervous system disease
Internal medicine
Placebo
Randomization

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

288

Citations